The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Condensate-driven transcriptional reprogramming to define core vulnerabilities in esophageal and gastric cancers.
 
Luis Alvarez
No Relationships to Disclose
 
Alberto Ocaña
No Relationships to Disclose
 
Andres Tejedor
No Relationships to Disclose
 
Juan Antonio Ardura
No Relationships to Disclose
 
Verónica Alonso
No Relationships to Disclose
 
Carlos Alonso Moreno
No Relationships to Disclose
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Abbvie; Affimed Therapeutics; AstraZeneca; Basilea; Bayer; BMS; Ellipses Pharma; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer; Pierre Fabre
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ADC Therapeutics (Inst); Amgen (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); Biomea Fusion (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Crescendo Bioscience (Inst); Cullinan Oncology (Inst); E-therapeutics (Inst); Eisai (Inst); F-Star Biotechnology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); hemavant (Inst); HiFiBiO Therapeutics (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Menarini (Inst); Merck (Inst); MonTa Biosciences (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Revolution Medicines (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - BMS
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - BeiGene; CHUV; European Organisation for Research and Treatment of Cancer (EORTC); Oncomatryx; PharmaMar; Sanofi; Shionogi; START
Stock and Other Ownership Interests - HM Hospitales; Oncoart Associated; START
Consulting or Advisory Role - Abbvie; Anaveon; Aromics; AstraZeneca/MedImmune; Chugai Pharma; Column Group; Debiopharm Group; Ellipses Pharma; Genmab; Grey Wolf Therapeutics; Incyte; Janssen-Cilag; Kivu; Medsir; MonTa Biosciences; Roche/Genentech; Servier; TargImmune Therapeutics; Weber Spain
Research Funding - START
Other Relationship - CRIS Cancer Foundation; Foundation PharmaMar; Investigational Therapeutics in Oncological Sciences
 
Balazs Gyorffy
Consulting or Advisory Role - Gedeon Richter
 
Jorge Rene Espinosa
No Relationships to Disclose
 
Irene Gutierrez Rojas
No Relationships to Disclose